List of antibody drugs

This list includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA approved therapeutic monoclonal antibodies in the Monoclonal antibody therapy page.

https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies

Name	Trade name	Type	Source	Target	Use
3F8		mab	mouse	GD2 ganglioside	neuroblastoma
8H9		mab	mouse	B7-H3	neuroblastoma, sarcoma, metastatic brain cancers
Abagovomab		mab	mouse	CA-125 (imitation)	ovarian cancer
Abciximab	ReoPro	Fab	chimeric	CD41 (integrin alpha-IIb)	platelet aggregation inhibitor
Abituzumab		mab	humanized	CD51	cancer
Abrilumab		mab	human	integrin α4β7	inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab		mab	human	Clostridium difficile	Clostridium difficile colitis
Adalimumab	Humira	mab	human	TNF-α	Rheumatoid arthritis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hemolytic disease of the newborn
Adecatumumab		mab	human	EpCAM	prostate and breast cancer
Aducanumab		mab	human	beta-amyloid	Alzheimer's disease
Afasevikumab		mab	human	IL17A and IL17F
Afelimomab		F(ab')2	mouse	TNF-α	sepsis
Afutuzumab		mab	humanized	CD20	lymphoma
Alacizumab pegol		F(ab')2	humanized	VEGFR2	cancer
ALD518			humanized	IL-6	rheumatoid arthritis
Alemtuzumab	Lemtrada, Campath	mab	humanized	CD52	Multiple sclerosis
Alirocumab		mab	human	PCSK9	hypercholesterolemia
Altumomab pentetate	Hybri-ceaker	mab	mouse	CEA	colorectal cancer (diagnosis)
Amatuximab		mab	chimeric	mesothelin	cancer
Anatumomab mafenatox		Fab	mouse	TAG-72	non-small cell lung carcinoma
Anetumab ravtansine		mab	human	MSLN	cancer
Anifrolumab		mab	human	interferon α/β receptor	systemic lupus erythematosus
Anrukinzumab		mab	humanized	IL-13	asthma
Apolizumab		mab	humanized	HLA-DR?	hematological cancers
Arcitumomab	CEA-Scan	Fab'	mouse	CEA	gastrointestinal cancers (diagnosis)
Ascrinvacumab		mab	human	activin receptor-like kinase 1	cancer
Aselizumab		mab	humanized	L-selectin (CD62L)	severely injured patients
Atezolizumab		mab	humanized	CD274	cancer
Atinumab		mab	human	RTN4
Atlizumab (= tocilizumab)	Actemra, RoActemra	mab	humanized	IL-6 receptor	rheumatoid arthritis
Atorolimumab		mab	human	Rhesus factor	hemolytic disease of the newbornTemplate:Citation needed
Avelumab		mab	human	CD274
Bapineuzumab		mab	humanized	beta amyloid	Alzheimer's disease
Basiliximab	Simulect	mab	chimeric	CD25 (α chain of IL-2 receptor)	prevention of organ transplant rejections
Bavituximab		mab	chimeric	phosphatidylserine	cancer, viral infections
Bectumomab	LymphoScan	Fab'	mouse	CD22	non-Hodgkin's lymphoma (detection)
Begelomab		mab	mouse	DPP4
Belimumab	Benlysta, LymphoStat-B	mab	human	BAFF	non-Hodgkin lymphoma etc.
Benralizumab		mab	humanized	CD125	asthma
Bertilimumab		mab	human	CCL11 (eotaxin-1)	severe allergic disorders
Besilesomab	Scintimun	mab	mouse	CEA-related antigen	inflammatory lesions and metastases (detection)
Bevacizumab	Avastin	mab	humanized	VEGF-A	metastatic cancer, retinopathy of prematurity
Bezlotoxumab		mab	human	Clostridium difficile	Clostridium difficile colitis
Biciromab	FibriScint	Fab'	mouse	fibrin II, beta chain	thromboembolism (diagnosis)
Bimagrumab		mab	human	ACVR2B	myostatin inhibitor
Bimekizumab		mab	humanized	IL 17A and IL 17F
Bivatuzumab mertansine		mab	humanized	CD44 v6	squamous cell carcinoma
Bleselumab		mab	human	CD40
Blinatumomab		BiTE	mouse	CD19	pre-B ALL (CD19+)
Blontuvetmab	Blontress	mab	veterinary	CD20
Blosozumab		mab	humanized	SOST	osteoporosis
Bococizumab		mab	humanized	neural apoptosis-regulated proteinase 1	dyslipidemia
Brazikumab		mab	human	IL23	Crohn's disease
Brentuximab vedotin		mab	chimeric	CD30 (TNFRSF8)	hematologic cancers
Briakinumab		mab	human	IL-12, IL-23	psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab		mab	human	IL-17	inflammatory diseases
Brolucizumab		mab	humanized	VEGFA	wet age-related macular degeneration
Brontictuzumab		mab	humanized	Notch 1	cancer
Burosumab		mab	human	FGF 23	X-linked hypophosphatemia
Cabiralizumab		mab	humanized	CSF1R
Canakinumab	Ilaris	mab	human	IL-1?	rheumatoid arthritis
Cantuzumab mertansine		mab	humanized	mucin CanAg	colorectal cancer etc.
Cantuzumab ravtansine		mab	humanized	MUC1	cancers
Caplacizumab		mab	humanized	VWF	thrombotic thrombocytopenic purpura, thrombosis
Capromab pendetide	Prostascint	mab	mouse	prostatic carcinoma cells	prostate cancer (detection)
Carlumab		mab	human	MCP-1	oncology/immune indications
Carotuximab		mab	chimeric	endoglin
Catumaxomab	Removab	3funct	rat/mouse hybrid	EpCAM, CD3	ovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugate		mab	humanized	Lewis-Y antigen	cancer
Cedelizumab		mab	humanized	CD4	prevention of organ transplant rejections, treatment of autoimmune diseases
Cergutuzumab amunaleukin		mab	humanized	IL2
Certolizumab pegol	Cimzia	Fab'	humanized	TNF-α	Crohn's disease Rheumatoid arthritis axial spondyloarthritis psoriasis arthritis
Cetuximab	Erbitux	mab	chimeric	EGFR	metastatic colorectal cancer and head and neck cancer
Citatuzumab bogatox		Fab	humanized	EpCAM	ovarian cancer and other solid tumors
Cixutumumab		mab	human	IGF-1 receptor (CD221)	solid tumors
Clazakizumab		mab	humanized	Oryctolagus cuniculus	rheumatoid arthritis
Clenoliximab		mab	chimeric	CD4	rheumatoid arthritis
Clivatuzumab tetraxetan	hPAM4-Cide	mab	humanized	MUC1	pancreatic cancer
Codrituzumab		mab	humanized	glypican 3	cancer
Coltuximab ravtansine		mab	chimeric	CD19	cancer
Conatumumab		mab	human	TRAIL-R2	cancer
Concizumab		mab	humanized	TFPI	bleeding
Crenezumab		mab	humanized	1-40-β-amyloid	Alzheimer's disease
Crotedumab		mab	human	GCGR	diabetes
CR6261		mab	human	Influenza A hemagglutinin	infectious disease/influenza A
Dacetuzumab		mab	humanized	CD40	hematologic cancers
Daclizumab	Zenapax	mab	humanized	CD25 (α chain of IL-2 receptor)	prevention of organ transplant rejections
Dalotuzumab		mab	humanized	IGF-1 receptor (CD221)	cancer etc.
Dapirolizumab pegol		mab	humanized	CD154 (CD40L)
Daratumumab		mab	human	CD38 (cyclic ADP ribose hydrolase)	cancer
Dectrekumab		mab	human	IL-13
Demcizumab		mab	humanized	DLL4	cancer
Denintuzumab mafodotin		mab	humanized	CD19	cancer
Denosumab	Prolia	mab	human	RANKL	osteoporosis, bone metastases etc.
Depatuxizumab mafodotin		mab	chimeric/humanized	EGFR	cancer
Derlotuximab biotin		mab	chimeric	histone complex	recurrent glioblastoma multiforme
Detumomab		mab	mouse	B-lymphoma cell	lymphoma
Dinutuximab		mab	chimeric	GD2 ganglioside	neuroblastoma
Diridavumab		mab	human	hemagglutinin	influenza A
Domagrozumab		mab	humanized	GDF-8	Duchenne muscular dystrophy
Dorlimomab aritox		F(ab')2	mouse
Drozitumab		mab	human	DR5	cancer etc.
Duligotumab		mab	human	ERBB3 (HER3)	testicular cancer
Dupilumab		mab	human	IL4	atopic diseases
Durvalumab		mab	human	CD274	cancer
Dusigitumab		mab	human	ILGF2	cancer
Ecromeximab		mab	chimeric	GD3 ganglioside	malignant melanoma
Eculizumab	Soliris	mab	humanized	C5	paroxysmal nocturnal hemoglobinuria, atypical HUS
Edobacomab		mab	mouse	endotoxin	sepsis caused by Gram-negative bacteria
Edrecolomab	Panorex	mab	mouse	EpCAM	colorectal carcinoma
Efalizumab	Raptiva	mab	humanized	LFA-1 (CD11a)	psoriasis (blocks T-cell migration)
Efungumab	Mycograb	scFv	human	Hsp90	invasive Candida infection
Eldelumab		mab	human	interferon gamma-induced protein	Crohn's disease, ulcerative colitis
Elgemtumab		mab	human	ERBB3 (HER3)	cancer
Elotuzumab		mab	humanized	SLAMF7	multiple myeloma
Elsilimomab		mab	mouse	IL-6
Emactuzumab		mab	humanized	CSF1R	cancer
Emibetuzumab		mab	humanized	HHGFR	cancer
Emicizumab		mab	humanized	activated F9, F10	haemophilia A
Enavatuzumab		mab	humanized	TWEAK receptor	cancer etc.
Enfortumab vedotin	mab	human	AGS-22M6	cancer expressing Nectin-4
Enlimomab pegol		mab	mouse	ICAM-1 (CD54)
Enoblituzumab		mab	humanized	CD276	cancer
Enokizumab		mab	humanized	IL9	asthma
Enoticumab		mab	human	DLL4
Ensituximab		mab	chimeric	5AC	cancer
Epitumomab cituxetan		mab	mouse	episialin
Epratuzumab		mab	humanized	CD22	cancer, SLE
Erenumab		mab	human	CGRP	migraine
Erlizumab		F(ab')2	humanized	ITGB2 (CD18)	heart attack, stroke, traumatic shock
Ertumaxomab	Rexomun	3funct	rat/mouse hybrid	HER2/neu, CD3	breast cancer etc.
Etaracizumab	Abegrin	mab	humanized	integrin αvβ3	melanoma, prostate cancer, ovarian cancer etc.
Etrolizumab		mab	humanized	integrin α7 β7	inflammatory bowel disease
Evinacumab		mab	human	angiopoietin 3	dyslipidemia
Evolocumab		mab	human	PCSK9	hypercholesterolemia
Exbivirumab		mab	human	hepatitis B surface antigen	hepatitis B
Fanolesomab	NeutroSpec	mab	mouse	CD15	appendicitis (diagnosis)
Faralimomab		mab	mouse	interferon receptor
Farletuzumab		mab	humanized	folate receptor 1	ovarian cancer
Fasinumab		mab	human	HNGF	acute sciatic pain
FBTA05	Lymphomun	3funct	rat/mouse hybrid	CD20	chronic lymphocytic leukaemia
Felvizumab		mab	humanized	respiratory syncytial virus	respiratory syncytial virus infection
Fezakinumab		mab	human	IL-22	rheumatoid arthritis, psoriasis
Fibatuzumab		mab	humanized	ephrin receptor A3
Ficlatuzumab		mab	humanized	HGF	cancer etc.
Figitumumab		mab	human	IGF-1 receptor (CD221)	adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab		mab	human	influenza A virus hemagglutinin
Flanvotumab		mab	human	TYRP1(glycoprotein 75)	melanoma
Fletikumab		mab	human	IL 20	rheumatoid arthritis
Fontolizumab	HuZAF	mab	humanized	IFN-γ	Crohn's disease etc.
Foralumab	mab	human	CD3 epsilon
Foravirumab		mab	human	rabies virus glycoprotein	rabies (prophylaxis)
Fresolimumab		mab	human	TGF-β	idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Fulranumab		mab	human	NGF	pain
Futuximab		mab	chimeric	EGFR	cancer
Galcanezumab		mab	humanized	calcitonin	migraine
Galiximab		mab	chimeric	CD80	B-cell lymphoma
Ganitumab		mab	human	IGF-1 receptor (CD221)	cancer
Gantenerumab		mab	human	beta amyloid	Alzheimer's disease
Gavilimomab		mab	mouse	CD147 (basigin)	graft versus host disease
Gemtuzumab ozogamicin	Mylotarg	mab	humanized	CD33	acute myelogenous leukemia
Gevokizumab		mab	humanized	IL-1β	diabetes etc.
Girentuximab	Rencarex	mab	chimeric	carbonic anhydrase 9 (CA-IX)	clear cell renal cell carcinoma<ref>http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html</ref>
Glembatumumab vedotin		mab	human	GPNMB	melanoma, breast cancer
Golimumab	Simponi	mab	human	TNF-α	rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab		mab	chimeric	CD23 (IgE receptor)	allergic asthma
Guselkumab		mab	human	IL23	psoriasis
Ibalizumab		mab	humanized	CD4	HIV infection
Ibritumomab tiuxetan	Zevalin	mab	mouse	CD20	non-Hodgkin's lymphoma
Icrucumab		mab	human	VEGFR-1	cancer etc.
Idarucizumab		mab	humanized	dabigatran	reversal of anticoagulant effects of dabigatran
Igovomab	Indimacis-125	F(ab')2	mouse	CA-125	ovarian cancer (diagnosis)
IMAB362		mab	human	CLDN18.2	gastrointestinal adenocarcinomas and pancreatic tumor
Imalumab		mab	human	MIF	cancer
Imciromab	Myoscint	mab	mouse	cardiac myosin	cardiac imaging
Imgatuzumab		mab	humanized	EGFR	cancer
Inclacumab		mab	human	selectin P	cardiovascular disease
Indatuximab ravtansine		mab	chimeric	SDC1	cancer
Indusatumab vedotin		mab	human	GUCY2C	cancer
Inebilizumab		mab	humanized	CD19	cancer, systemic sclerosis, multiple sclerosis
Infliximab	Remicade	mab	chimeric	TNF-α	rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab		mab	human	CD51	solid tumors (prostate cancer, melanoma)
Inolimomab		mab	mouse	CD25 (α chain of IL-2 receptor)	graft versus host disease
Inotuzumab ozogamicin		mab	humanized	CD22	ALL
Ipilimumab	Yervoy	mab	human	CD152	melanoma
Iratumumab		mab	human	CD30 (TNFRSF8)	Hodgkin's lymphoma
Isatuximab		mab	chimeric	CD38	cancer
Itolizumab		mab	humanized	CD6
Ixekizumab		mab	humanized	IL 17A	autoimmune diseases
Keliximab		mab	chimeric	CD4	chronic asthma
Labetuzumab	CEA-Cide	mab	humanized	CEA	colorectal cancer
Lampalizumab		mab	humanized	CFD	geographic atrophy secondary to age-related macular degeneration
Lanadelumab		mab	human	kallikrein	angioedema
Landogrozumab		mab	humanized	GDF-8	muscle wasting disorders
Laprituximab emtansine		mab	chimeric	EGFR
Lebrikizumab		mab	humanized	IL-13	asthma
Lemalesomab		mab	mouse	NCA-90 (granulocyte antigen)	diagnostic agent
Lendalizumab		mab	humanized	C5
Lenzilumab		mab	human	CSF2
Lerdelimumab		mab	human	TGF beta 2	reduction of scarring after glaucoma surgery
Lexatumumab		mab	human	TRAIL-R2	cancer
Libivirumab		mab	human	hepatitis B surface antigen	hepatitis B
Lifastuzumab vedotin		mab	humanized	phosphate-sodium co-transporter	cancer
Ligelizumab		mab	humanized	IGHE	severe asthma and chronic spontaneous urticaria
Lilotomab satetraxetan		mab	mouse	CD37	cancer
Lintuzumab		mab	humanized	CD33	cancer
Lirilumab		mab	human	KIR2D	solid and hematological cancers
Lodelcizumab		mab	humanized	PCSK9	hypercholesterolemia
Lokivetmab		mab	veterinary	Canis lupus familiaris IL31
Lorvotuzumab mertansine		mab	humanized	CD56	cancer
Lucatumumab		mab	human	CD40	multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol		mab	humanized	CD28	autoimmune diseases
Lumiliximab		mab	chimeric	CD23 (IgE receptor)	chronic lymphocytic leukemia
Lumretuzumab		mab	humanized	ERBB3 (HER3)	cancer
MABp1	Xilonix	mab	human	IL1A	colorectal cancer
Mapatumumab		mab	human	TRAIL-R1	cancer
Margetuximab		mab	humanized	ch4D5	cancer
Maslimomab			mouse	T-cell receptor
Mavrilimumab		mab	human	GMCSF receptor α-chain	rheumatoid arthritis
Matuzumab		mab	humanized	EGFR	colorectal, lung and stomach cancer
Mepolizumab	Bosatria	mab	humanized	IL-5	asthma and white blood cell diseases
Metelimumab		mab	human	TGF beta 1	systemic scleroderma
Milatuzumab		mab	humanized	CD74	multiple myeloma and other hematological malignancies
Minretumomab		mab	mouse	TAG-72	tumor detection (and therapy?)
Mirvetuximab soravtansine		mab	chimeric	folate receptor alpha	cancer
Mitumomab		mab	mouse	GD3 ganglioside	small cell lung carcinoma
Mogamulizumab		mab	humanized	CCR4	cancer
Monalizumab		mab	humanized	KLRC1
Morolimumab		mab	human	Rhesus factor
Motavizumab	Numax	mab	humanized	respiratory syncytial virus	respiratory syncytial virus (prevention)
Moxetumomab pasudotox		mab	mouse	CD22	cancer
Muromonab-CD3	Orthoclone OKT3	mab	mouse	CD3	prevention of organ transplant rejections
Nacolomab tafenatox		Fab	mouse	C242 antigen	colorectal cancer
Namilumab		mab	human	CSF2
Naptumomab estafenatox		Fab	mouse	5T4	non-small cell lung carcinoma, renal cell carcinoma
Naratuximab emtansine		mab	chimeric	CD37
Narnatumab		mab	human	RON	cancer
Natalizumab	Tysabri	mab	humanized	integrin α4	multiple sclerosis, Crohn's disease
Navicixizumab		mab	chimeric/humanized	DLL4
Navivumab		mab	human	influenza A virus hemagglutinin HA
Nebacumab		mab	human	endotoxin	sepsis
Necitumumab		mab	human	EGFR	non-small cell lung carcinoma
Nemolizumab		mab	humanized	IL31RA	eczema
Nerelimomab		mab	mouse	TNF-α
Nesvacumab		mab	human	angiopoietin 2	cancer
Nimotuzumab	Theracim, Theraloc	mab	humanized	EGFR	squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nivolumab	Opdivo	mab	human	PD-1	cancer
Nofetumomab merpentan	Verluma	Fab	mouse		cancer (diagnosis)
Obiltoxaximab		mab	chimeric	Bacillus anthracis anthrax	Bacillus anthracis spores
Obinutuzumab	Gazyva	mab	humanized	CD20	Chronic lymphatic leukemia
Ocaratuzumab		mab	humanized	CD20	cancer
Ocrelizumab		mab	humanized	CD20	rheumatoid arthritis, lupus erythematosus etc.
Odulimomab		mab	mouse	LFA-1 (CD11a)	prevention of organ transplant rejections, immunological diseases
Ofatumumab	Arzerra	mab	human	CD20	chronic lymphocytic leukemia etc.
Olaratumab		mab	human	PDGF-R α	cancer
Olokizumab		mab	humanized	IL6
Omalizumab	Xolair	mab	humanized	IgE Fc region	allergic asthma
Onartuzumab		mab	humanized	human scatter factor receptor kinase	cancer
Ontuxizumab		mab	chimeric/humanized	TEM1	cancer
Opicinumab	mab	human	LINGO-1	multiple sclerosis
Oportuzumab monatox		scFv	humanized	EpCAM	cancer
Oregovomab	OvaRex	mab	mouse	CA-125	ovarian cancer
Orticumab		mab	human	oxLDL
Otelixizumab		mab	chimeric/humanized	CD3	diabetes mellitus type 1
Otlertuzumab		mab	humanized	CD37	cancer
Oxelumab		mab	human	OX-40	asthma
Ozanezumab		mab	humanized	NOGO-A	ALS and multiple sclerosis
Ozoralizumab		mab	humanized	TNF-α	inflammation
Pagibaximab		mab	chimeric	lipoteichoic acid	sepsis (Staphylococcus)
Palivizumab	Synagis, Abbosynagis	mab	humanized	F protein of respiratory syncytial virus	respiratory syncytial virus (prevention)
Pamrevlumab		mab	human	CTGF	idiopathic pulmonary fibrosis (IPF), pancreatic cancer
Panitumumab	Vectibix	mab	human	EGFR	colorectal cancer
Pankomab		mab	humanized	tumor specific glycosylation of MUC1	ovarian cancer
Panobacumab		mab	human	Pseudomonas aeruginosa	Pseudomonas aeruginosa infection
Parsatuzumab		mab	human	EGFL7	cancer
Pascolizumab		mab	humanized	IL-4	asthma
Pasotuxizumab		mab	chimeric/humanized	folate hydrolase	cancer
Pateclizumab		mab	humanized	LTA	TNF
Patritumab		mab	human	ERBB3 (HER3)	cancer
Pembrolizumab		mab	humanized	PDCD1	melanoma and other cancers
Pemtumomab	Theragyn		mouse	MUC1	cancer
Perakizumab		mab	humanized	IL 17A	arthritis
Pertuzumab	Omnitarg	mab	humanized	HER2/neu	cancer
Pexelizumab		scFv	humanized	C5	reduction of side effects of cardiac surgery
Pidilizumab		mab	humanized	PD-1	cancer and infectious diseases
Pinatuzumab vedotin		mab	humanized	CD22	cancer
Pintumomab		mab	mouse	adenocarcinoma antigen	adenocarcinoma (imaging)
Placulumab		mab	human	human TNF	pain and inflammatory diseases
Plozalizumab		mab	humanized	CCR2	diabetic nephropathy and arteriovenous graft patency
Pogalizumab		mab	humanized	TNFR superfamily member 4
Polatuzumab vedotin		mab	humanized	CD79B	cancer
Ponezumab		mab	humanized	human beta-amyloid	Alzheimer's disease
Prezalizumab		mab	humanized	ICOSL
Priliximab		mab	chimeric	CD4	Crohn's disease, multiple sclerosis
Pritoxaximab		mab	chimeric	E. coli shiga toxin type-1
Pritumumab		mab	human	vimentin	brain cancer
PRO 140			humanized	CCR5	HIV infection
Quilizumab		mab	humanized	IGHE	asthma
Racotumomab		mab	mouse	N-glycolylneuraminic acid	cancer
Radretumab		mab	human	fibronectin extra domain-B	cancer
Rafivirumab		mab	human	rabies virus glycoprotein	rabies (prophylaxis)
Ralpancizumab		mab	humanized	neural apoptosis-regulated proteinase 1	dyslipidemia
Ramucirumab	Cyramza	mab	human	VEGFR2	solid tumors
Ranibizumab	Lucentis	Fab	humanized	VEGF-A	macular degeneration (wet form)
Raxibacumab		mab	human	anthrax toxin, protective antigen	anthrax (prophylaxis and treatment)
Refanezumab		mab	humanized	myelin-associated glycoprotein	recovery of motor function after stroke
Regavirumab		mab	human	cytomegalovirus glycoprotein B	cytomegalovirus infection
Reslizumab		mab	humanized	IL-5	inflammations of the airways, skin and gastrointestinal tract
Rilotumumab		mab	human	HGF	solid tumors
Rinucumab		mab	human	platelet-derived growth factor receptor beta	neovascular age-related macular degeneration
Risankizumab		mab	humanized	IL23A
Rituximab	MabThera, Rituxan	mab	chimeric	CD20	lymphomas, leukemias, some autoimmune disorders
Rivabazumab pegol		mab	humanized	Pseudomonas aeruginosa type III secretion system
Robatumumab		mab	human	IGF-1 receptor (CD221)	cancer
Roledumab		mab	human	RHD
Romosozumab		mab	humanized	sclerostin	osteoporosis
Rontalizumab		mab	humanized	IFN-α	systemic lupus erythematosus
Rovalpituzumab tesirine		mab	humanized	DLL3
Rovelizumab	LeukArrest	mab	humanized	CD11, CD18	haemorrhagic shock etc.
Ruplizumab	Antova	mab	humanized	CD154 (CD40L)	rheumatic diseases
Sacituzumab govitecan		mab	humanized	tumor-associated calcium signal transducer 2	cancer
Samalizumab		mab	humanized	CD200	cancer
Sapelizumab		mab	humanized	IL6R
Sarilumab		mab	human	IL6	rheumatoid arthritis, ankylosing spondylitis
Satumomab pendetide		mab	mouse	TAG-72	cancer (diagnosis)
Secukinumab		mab	human	IL 17A	uveitis, rheumatoid arthritis psoriasis
Seribantumab		mab	human	ERBB3 (HER3)	cancer
Setoxaximab		mab	chimeric	E. coli shiga toxin type-2
Sevirumab			human	cytomegalovirus	cytomegalovirus infection
Sibrotuzumab		mab	humanized	FAP	cancer
SGN-CD19A		mab	humanized	CD19	acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SGN-CD33A		mab	humanized	CD33	Acute myeloid leukemia
Sifalimumab		mab	humanized	IFN-α	SLE, dermatomyositis, polymyositis
Siltuximab		mab	chimeric	IL-6	cancer
Simtuzumab		mab	humanized	LOXL2	fibrosis
Siplizumab		mab	humanized	CD2	psoriasis, graft-versus-host disease (prevention)
Sirukumab		mab	human	IL-6	rheumatoid arthritis
Sofituzumab vedotin		mab	humanized	CA-125	ovarian cancer
Solanezumab		mab	humanized	beta amyloid	Alzheimer's disease
Solitomab		BiTE	mouse	EpCAM
Sonepcizumab			humanized	sphingosine-1-phosphate	choroidal and retinal neovascularization
Sontuzumab		mab	humanized	episialin
Stamulumab		mab	human	myostatin	muscular dystrophy
Sulesomab	LeukoScan	Fab'	mouse	NCA-90 (granulocyte antigen)	osteomyelitis (imaging)
Suvizumab		mab	humanized	HIV-1	viral infections
Tabalumab		mab	human	BAFF	B-cell cancers
Tacatuzumab tetraxetan	AFP-Cide	mab	humanized	alpha-fetoprotein	cancer
Tadocizumab		Fab	humanized	integrin αIIbβ3	percutaneous coronary intervention
Talizumab		mab	humanized	IgE	allergic reaction
Tamtuvetmab	Tactress	mab	veterinary	CD52
Tanezumab		mab	humanized	NGF	pain
Taplitumomab paptox		mab	mouse	CD19	cancerTemplate:Citation needed
Tarextumab		mab	human	Notch receptor	cancer
Tefibazumab	Aurexis	mab	humanized	clumping factor A	Staphylococcus aureus infection
Telimomab aritox		Fab	mouse
Tenatumomab		mab	mouse	tenascin C	cancer
Teneliximab		mab	chimeric	CD40	autoimmune diseases and prevention of organ transplant rejection
Teplizumab		mab	humanized	CD3	diabetes mellitus type 1
Teprotumumab		mab	human	IGF-1 receptor (CD221)	hematologic tumors
Tesidolumab		mab	human	C5
Tetulomab		mab	humanized	CD37	cancer Template:Cite journal
Tezepelumab		mab	human	TSLP	asthma, atopic dermatitis
TGN1412			humanized	CD28	chronic lymphocytic leukemia, rheumatoid arthritis
Ticilimumab (= tremelimumab)		mab	human	CTLA-4	cancer
Tildrakizumab		mab	humanized	IL23	immunologically mediated inflammatory disorders
Tigatuzumab		mab	humanized	TRAIL-R2	cancer
Timolumab		mab	human	AOC3
Tisotumab vedotin	mab	human	coagulation factor III
TNX-650			humanized	IL-13	Hodgkin's lymphoma
Tocilizumab (= atlizumab)	Actemra, RoActemra	mab	humanized	IL-6 receptor	rheumatoid arthritis
Toralizumab		mab	humanized	CD154 (CD40L)	rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab		mab	human	Staphylococcus aureus
Tositumomab	Bexxar		mouse	CD20	follicular lymphoma
Tovetumab		mab	human	CD140a	cancer
Tralokinumab		mab	human	IL-13	asthma etc.
Trastuzumab	Herceptin	mab	humanized	HER2/neu	breast cancer
Trastuzumab emtansine	Kadcyla	mab	humanized	HER2/neu	breast cancer
TRBS07>	Ektomab	3funct		GD2 ganglioside	melanoma
Tregalizumab		mab	humanized	CD4
Tremelimumab		mab	human	CTLA-4	cancer
Trevogrumab		mab	human	growth differentiation factor 8	muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin		mab	humanized	EpCAM	cancer
Tuvirumab			human	hepatitis B virus	chronic hepatitis B
Ublituximab		mab	chimeric	MS4A1	cancer
Ulocuplumab		mab	human	CXCR4 (CD184)	hematologic malignancies
Urelumab		mab	human	4-1BB (CD137)	cancer etc.
Urtoxazumab		mab	humanized	Escherichia coli	diarrhoea caused by E. coli
Ustekinumab	Stelara	mab	human	IL-12, IL-23	multiple sclerosis, psoriasis, psoriatic arthritis
Utomilumab		mab	human	4-1BB (CD137)	cancer
Vadastuximab talirine		mab	chimeric	CD33
Vandortuzumab vedotin		mab	humanized	STEAP1	cancer
Vantictumab		mab	human	Frizzled receptor	cancer
Vanucizumab		mab	humanized	angiopoietin 2	cancer
Vapaliximab		mab	chimeric	AOC3 (VAP-1)
Varlilumab		mab	human	CD27	solid tumors and hematologic malignancies
Vatelizumab		mab	humanized	ITGA2 (CD49b)
Vedolizumab	Entyvio	mab	humanized	integrin α4β7	Crohn's disease, ulcerative colitis
Veltuzumab		mab	humanized	CD20	non-Hodgkin's lymphoma
Vepalimomab		mab	mouse	AOC3 (VAP-1)	inflammation
Vesencumab		mab	human	NRP1	solid malignancies
Visilizumab	Nuvion	mab	humanized	CD3	Crohn's disease, ulcerative colitis
Vobarilizumab		mab	humanized	IL6R	inflammatory autoimmune diseases
Volociximab		mab	chimeric	integrin α5β1	solid tumors
Vorsetuzumab mafodotin		mab	humanized	CD70	cancer
Votumumab	HumaSPECT	mab	human	tumor antigen CTAA16.88	colorectal tumors
Xentuzumab		mab		IGF1, IGF2
Zalutumumab	HuMax-EGFr	mab	human	EGFR	squamous cell carcinoma of the head and neck
Zanolimumab	HuMax-CD4	mab	human	CD4	rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab		mab	chimeric	HER1	cancer
Ziralimumab		mab	human	CD147 (basigin)
Zolimomab aritox		mab	mouse	CD5	systemic lupus erythematosus, graft-versus-host disease